CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Feb 1;11(2):128-36. Unique Identifier : AIDSLINE MED/96147312
Ratto S; Sitz KV; Scherer AM; Loomis LD; Cox JH; Redfield RR; Birx DL; Henry M. Jackson Foundation, Rockville, MD 20850, USA.

Abstract: To define the epitopes present within the V3 loop sequence recognized by five HIV-1 envelope-specific T-cell lines, a panel of V3 LAI peptides bearing sequential truncations from both the N- and C-terminus was synthesized and tested for their ability to induce proliferation. Each individual T-cell line had a different pattern of response against the truncated V3 peptides, demonstrating the presence of a cluster of CD4+ T-cell epitopes within the V3 loop. To assess the ability of these envelope-specific T-cell lines to recognize and proliferate in response to V3 loops of different viral strains, they were tested against a panel of heterologous V3 loop peptides derived from different viral genotypes within and outside of HIV-1 clade B. There was no proliferative response against heterologous V3 loops by any of the lines, demonstrating that recognition of the V3 epitopes is highly strain specific. One of the defined epitopes was shown to elicit a cytotoxic response as well, suggesting the multifaceted role that the CD4+ T cell might play in HIV-1 disease.

Keywords: Amino Acid Sequence Cell Line Cells, Cultured Cytotoxicity, Immunologic/IMMUNOLOGY CD4-Positive T-Lymphocytes/*IMMUNOLOGY Epitopes/*IMMUNOLOGY Gene Products, env/CHEMISTRY/IMMUNOLOGY Histocompatibility Antigens Class II/ANALYSIS Histocompatibility Testing Human HIV Envelope Protein gp120/CHEMISTRY/*IMMUNOLOGY HIV Infections/*IMMUNOLOGY HIV Seropositivity/*IMMUNOLOGY HIV-1/*IMMUNOLOGY Lymphocyte Transformation/IMMUNOLOGY Molecular Sequence Data Peptide Fragments/CHEMISTRY/*IMMUNOLOGY Protein Precursors/CHEMISTRY/IMMUNOLOGY T-Lymphocytes, Cytotoxic/IMMUNOLOGY JOURNAL ARTICLE
960530
M9651037

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .